BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 12514710)

  • 21. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DermaVir, a novel HIV immunisation technology.
    Lori F; Trocio J; Bakare N; Kelly LM; Lisziewicz J
    Vaccine; 2005 Mar; 23(17-18):2030-4. PubMed ID: 15755566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunity in natural SIV infections.
    Silvestri G
    J Intern Med; 2009 Jan; 265(1):97-109. PubMed ID: 19093963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
    López A; van der Lubbe N; Sánchez-Palomino S; Arnedo M; Nomdedeu M; Castro P; Guilà M; Maleno MJ; García F; Gallart T; Gatell JM; Plana M
    Vaccine; 2009 Oct; 27(44):6166-78. PubMed ID: 19712765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic T-cell epitopes in HIV/SIV infection.
    Venet A; Walker BD
    AIDS; 1993; 7 Suppl 1():S117-26. PubMed ID: 7689848
    [No Abstract]   [Full Text] [Related]  

  • 29. The primate connection.
    Trivedi B
    Nature; 2010 Jul; 466(7304):S5. PubMed ID: 20631704
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques.
    Kent SJ; De Rose R; Mokhonov VV; Mokhonova EI; Fernandez CS; Alcantara S; Rollman E; Mason RD; Loh L; Peut V; Reece JC; Wang XJ; Wilson KM; Suhrbier A; Khromykh A
    Virology; 2008 May; 374(2):528-34. PubMed ID: 18272194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What's the matter with HIV-directed killer T cells?
    Wick D; Self SG
    J Theor Biol; 2002 Nov; 219(1):19-31. PubMed ID: 12392972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection.
    Soloff AC; Liu X; Gao W; Day RD; Gambotto A; Barratt-Boyes SM
    Eur J Immunol; 2009 Sep; 39(9):2437-49. PubMed ID: 19670380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV CTL escape: at what cost?
    Smith SM
    Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccinology: Persistence pays off.
    Johnson RP
    Nature; 2011 May; 473(7348):456-7. PubMed ID: 21614068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of MHC class I diversity on immune control of immunodeficiency virus replication.
    Goulder PJ; Watkins DI
    Nat Rev Immunol; 2008 Aug; 8(8):619-30. PubMed ID: 18617886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
    Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
    Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is an HIV vaccine possible?
    McMichael AJ; Hanke T
    Nat Med; 1999 Jun; 5(6):612-4. PubMed ID: 10371492
    [No Abstract]   [Full Text] [Related]  

  • 39. AIDS vaccine developments.
    Cranage MP; Ashworth LA; Greenaway PJ; Murphey-Corb M; Desrosiers RC
    Nature; 1992 Feb; 355(6362):685-6. PubMed ID: 1741055
    [No Abstract]   [Full Text] [Related]  

  • 40. AIDS vaccine developments.
    Osterhaus A; de Vries P; Heeney J
    Nature; 1992 Feb; 355(6362):684-5. PubMed ID: 1741054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.